Prosecution Insights
Last updated: November 12, 2026
Application No. 18/605,750

METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES

Non-Final OA §102§112
Filed
Mar 14, 2024
Priority
Mar 17, 2023 — provisional 63/453,063 +1 more
Examiner
GAUGER, PAUL RANDALL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Escend Pharmaceuticals Inc.
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
68%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
16 granted / 27 resolved
-0.7% vs TC avg
Moderate +8% lift
Without
With
+8.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
17 currently pending
Career history
45
Total Applications
across all art units

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgement is made of Applicant’s claim for benefit under 35 U.S.C. §119(e) to United States Provisional Patent Application Serial No. 63/453,063, filed March 17, 2023, and U.S. Provisional application No. 63/453,068, filed March 18, 2023. Requirement for Election/Restriction -Status of the Claims In response to the Restriction Requirement mailed on 05/19/2026, Applicants have made a proper election of species in their reply filed on 07/20/2026. Election was made with traverse of the following: The following species elections are selected: 1) Single Specific Dosing Regimen Administered a. Claim 1: Formula 1 is elected: 6,6' ,7, 12-tetramethoxy-2,2'-dimethyl-berbaman (tetrandrine) as the dosing regimen compound, b. Claim 3. a. before treatment with ASTX727, or other chemotherapeutic regimens, or immunologic therapeutics; as the timing of dosing Formula l; c. Claim 6: Oral administration as the method of administration of a solid composition (Claim 19); d. Frequency/duration of Administration as provided in claims 7-12: i. Claim 7: Interval is: hours by oral administration; ii Frequency: Claim 8: split into increments to be given multiple times per day. Claim 11: tetrandrine administration is chronically administered and iii. Claim 12: Dosing Frequency: a single dose ranging from 20 to 450 mg/m2 each time, which could be 3 times per day (further limiting claim 1 dose); iv. Claim 18: Other drug agent administered: Inqovi ((ASTX727), Cedazuridine and Decitabine). 2) Single Specific Patient Population Applicants elect myelodysplastic syndrome (MDS) as the specific patient population. With acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML) as developing from MDS depending on when diagnosis occurs. Applicant has withdrawn claims 13-14 and 32. Claims 5, 9, 20-31 are withdrawn from consideration as not being drawn to the elected species of the single specific dosing regimen (as in claims 5 and 9) or the specific patient population (as in claims 20-31) as required by the restriction requirement dated 05/19/2026. Claims 1-36 are pending in the current application and examined on their merits, Claim Objections Claims 1, 3, 4, 6, 7, and 15 are objected to because of the following informalities: In claims 1, 3, 4, 6, 7, and 15 all claims identify sections of the claim that include “a.” The proper form when referring to a subset of the claim should read “a.)”, including the other subsets (b-d). Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and its dependent claims 2-8, 10-12, 15-19, and 33-36 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 applicant purports to have invented method for treating preneoplastic and neoplastic diseases and solid tumors in a subject in need thereof comprising administering to the subject a compound of Formula I (tetrandrine) as shown below. Claim 1 further limits, in section a, the variables of R1 and R1’ as: “where R1 and R1' are the same or different short chained carbon-based ligands including without limitation, CH3, CO2CH3 or H; and R2 is CH3 or C2Hs; and R3 is CH3 or hydrogen, has the "S" isomeric configuration at the C-1' chiral carbon location” PNG media_image1.png 211 369 media_image1.png Greyscale Claim 1 and each of the dependent claims are indefinite for reciting the phrase “without limitation” as variable options for R1 and R1'. One of ordinary skill in the art cannot reasonably determine the metes and bounds of the limitation as described by the applicant because when the selection of variables in a compound are selected from listed options “without limitation”. Claim 11 further limits claim 1 wherein said tetrandrine administration is chronically. One of ordinary skill in the art cannot reasonably determine the metes and bounds of the limitation as described by the applicant because administering a dose of tetrandrine “chronically” can mean a variety of patient conditions defined as being chronic or the administration of the compound is toxic to certain patients. Claim 12 further limits the method of claim 10 wherein the dose of tetrandrine is about a single dose ranging from 20 to 450 mg/m2 each time, which could be 3 times per day. Applicants elected the method of administration as an oral dose (as in claim 6) and hours as the frequency/duration (as in claim 7). One of ordinary skill in the art cannot reasonably determine the metes and bounds of the limitation as described by the applicant because administering a dose of tetrandrine as defined in hours for 3 days, although it is 36 hours, is that the end of the dose duration and is 3 times per day the maximum dose per day or the minimum? Is the condition identified in claim 1 remedied by the number of doses in 3 days or is the treatment shorter or longer? Claim 15 further limits the method of claim 1 to A method of administering to a patient in need of myeloablative conditioning prior to hematopoietic stem cell transplantation (HSCT) procedures, said method comprising: Administering a bisbenzylisoquinoline tetrandrine according to claim 1 to said patient in need of prior to administration of one or more myeloablative conditioning agents or procedures including: subsection xi.) Decitabine + Cedazuridine (ASTX727). The drug known as ASTX and is an oral medication that is a combination of decitabine (a chemotherapy drug/DNA hypomethylating agent) and cedazuridine (a cytidine deaminase inhibitor that prevents decitabine from breaking down in the gut and liver. One of ordinary skill in the art cannot reasonably determine the metes and bounds of the limitation as described by the applicant because administering tetrandrine to a patient in need of myeloablative conditioning prior to hematopoietic stem cell transplantation (HSCT) procedures would not utilize the elected compound is ASTX727 that is not a myeloablative conditioning agent, but rather a combination of a chemotherapeutic and a cytidine deaminase inhibitor. Claim 17 further limits the method of claim 15 “wherein tetrandrine or in the form of a derivative, isomer and/or analog, a modified form such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with a first other agent(s) and is administered along with a pharmaceutically acceptable acid, carrier and/or in a pharmaceutically compatible product or in combination with a second other agent(s).” The instant claim uses Exemplary Language “such as” to describe modified solid forms of tetrandrine or derivatives, isomers or analogs in combination with other agent(s). One of ordinary skill in the art cannot reasonably determine the metes and bounds of the limitation as described by the applicant because the language utilized “such as” does not identify a particular specific form. Claim Rejections – 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 2 and 10 rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Each of the claims 2 and 10 are directed to methods identified in clam 1 for treating preneoplastic and neoplastic diseases and solid tumors in a subject in need thereof comprising administering to the subject a compound of Formula I (tetrandrine), wherein the disease is selected from the group consisting of myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), leukemia and solid tumors and wherein an effective amount comprises 0.01 to 1000 mg/m2. Claim 2 refers to the method of claim 1 wherein the disease is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), MDS/MPN unclassifiable, acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), rnyeloproliferative svndrorne (MPS), and mvelofibrosis (MF). All the diseases are either preneoplastic or neoplastic diseases consisting of myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). Claim 10 refers to the method of claim 1 wherein the tetrandrine is administered to said patient in an amount of abeut 0.01 mg/m2 to 1000 mg/m2. Claim 1 in section c. details the effective amount of tetrandrine to treat the disease is selected from the group consisting of myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), leukemia and solid tumors is between 0.01 to 1000 mg/m2. None of these further limitations pertaining to the intended use further limit the structure of the composition. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 5-7, 10, 12, 18 and 19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wen-Lin Xu, et. al., Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia, Leukemia Research 30, (2006), pages 407–413, hereinafter referred to as Xu. Claim 1 recites methods for treating preneoplastic and neoplastic diseases and solid tumors in a subject in need thereof comprising administering to the subject a compound of Formula I (tetrandrine) wherein the disease is selected from the group consisting of myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), leukemia and solid tumors and wherein an effective amount comprises 0.01 to 1000 mg/m2. Xu teaches the use of tetrandrine (TET) to treat acute myeloid leukemia (AML) in a multicenter clinical trial of 38 patients (title and abstract). As the applicant points out in the traverse argument in the response to the restriction (07/20/2026), “both MDS and myeloproliferative neoplasms (MPN) can lead to the development of acute myeloid leukemia (AML) which also originates in the bone marrow”. Xu also teaches the dose of tetrandrine which was delivered orally and listed in mg/kg (as shown below). The instant application lists the value of tetrandrine in mg/m2. A conversion of the values from mg/m2 to mg/kg; assuming a 70 inch and 170-pound patient, the range listed in the instant application of (0.01-1000 mg/m2), equates to 0.02 mg/kg to 24 mg/kg. TET was administered orally as a pretreatment loading dose at 2 mg/kg, then 4 mg/ (kg day) for 5 days. Xu, p408, column 2, paragraph 1. Therefore, Xu anticipates the method of using the compound tetrandrine (TET) to treat acute myeloid leukemia (AML), a disease that results from both MDS and MPN, in a concentration of between the ranges of the instant application. Claim 2 further limits claim 1 and recites a group of diseases including acute myeloid leukemia (AML). As stated above, Xu anticipates the method of using the compound tetrandrine (TET) to treat acute myeloid leukemia (AML). Claim 3 and 18 further limits claim 2 (as in claim 3) and claim 17 (as in claim 18) the claims recite a Markush group of wherein the patient is administered tetrandrine in at least one treatment interval selected from the group consisting of other treatments that include daunorubicin, etoposide and cytarabine. Xu teaches the use of daunorubicin used in conjunction with tetrandrine (TET) in a clinical trial setting. For example: “In a multicenter clinical trial, 38 patients with poor risk forms of AML were treated with tetrandrine (TET), a potent inhibitor of the MDR-1 efflux pump, combined with daunorubicin (DNR), etoposide and cytarabine (TET–DEC).” Xu, Abstract, pg. 407 (emphasis added). Therefore, Xu anticipates the use of tetrandrine (TET) combined with daunorubicin (DNR), etoposide and cytarabine (TET–DEC) to treat AML in patients. Claim 6 and claim 19 further limit claim 1 a wherein tetrandrine is administered by the delivery method selected from at least one of the group consisting of (as in claim 6): a. orally, b. parenterally (infusion IV), and/or c. subcutaneously. and claim 19 requiring a solid composition selected from the group consisting of: a powder, a tablet, and a capsule. As shown in the rejection to claim 1 above, Xu anticipates the use of an oral dose of tetrandrine (TET) which also would be a tablet or a capsule. Claim 7 further limits claim 1 wherein the frequency of tetrandrine administration is by a delivery interval selected from at least one of the group consisting of: a. hours by oral administration; b. biweekly; c. progressive escalation of dosing based on patient tolerance; d. selected and intermittent boost dose administrations; e. dosing by a bolus, single, multiple daily and multiple doses/day, and f. release of the does that is at least one of immediate, slow, and controlled. As detailed in the rejection to claim 1 above, Xu teaches: “TET was administered orally as a pretreatment loading dose at 2 mg/kg, then 4 mg/(kg day) for 5 days;” Xu, p408, column 2, paragraph 1 (emphasis added). Therefore, Xu anticipates a dosage frequency of 24 hours or daily by oral administration of tetrandrine. Claim 10 further limits the method of claim 1 wherein the tetrandrine is administered to said patient in an amount of 0.01 mg/m2 to 1000 mg/m2. As detailed in the rejection to claim 1 above the relative amounts used by Xu A conversion of the values from mg/m2 to mg/kg; assuming a 70 inch and 170-pound patient, the range listed in the instant application of (0.01-1000 mg/m2), equates to 0.02 mg/kg to 24 mg/kg. Xu uses between 2 mg.kg and 4 mg/kg. A conversion of the values from mg/m2 to mg/kg; assuming a 70 inch and 170-pound patient, the range listed in the instant application of (0.01-1000 mg/m2), equates to 0.02 mg/kg to 24 mg/kg which falls between .01 and 1000 mg/m2. Therefore, Xu anticipates the range identified in the instant claim. Claim 12 further limits the method of claim 1 wherein the dose of said the tetrandrine is a single dose ranging from 20 to 450 mg/m2 each time, which could be 3 times per day. The conversion of mg/m2 using the same criteria as detailed in the rejection to claim 1 above would equate to 0.5-11.23 mg/kg. Clearly Xu is using a single dose of 2-4 mg/kg which falls within the applicant’s range of single dose criteria and although the applicant suggests that the dose could be 3 times per day, it is not required by the claim. Therefore, Xu anticipates the single dose range from 20-450 mg/m2 (0.5-11.23 mg/kg). Conclusion Claims 1, 3, 4, 6, 7, and 15 are objected. Claims 1, 2-8, 10-12, 15-19, and 33-36 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL RANDALL GAUGER whose telephone number is (571)272-1325. The examiner can normally be reached M-F 7:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffery Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P.R.G./Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Mar 14, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790300
STING MODULATORS, COMPOSITIONS, AND METHODS OF USE
4y 8m to grant Granted Nov 10, 2026
Patent 12758542
METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMA
3y 5m to grant Granted Oct 13, 2026
Patent 12728119
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING 3-KETOACYL CoA THIOLASE INHIBITOR AND CARNITINE ACYLCARNITINE CARRIER INHIBITOR
3y 8m to grant Granted Sep 08, 2026
Patent 12655151
ION CHANNEL MODULATORS
4y 0m to grant Granted Jun 16, 2026
Patent 12629357
TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER
3y 7m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
68%
With Interview (+8.3%)
Low
PTA Risk
Based on 27 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month